Drugs in ATC Class S01B

Up to Top Level ATC Classes

Up to S - Sensory organs

Up to S01 - OPHTHALMOLOGICALS

Subclasses in ATC: S01B - ANTIINFLAMMATORY AGENTS

S01BA - Corticosteroids, plain

S01BC - Antiinflammatory agents, non-steroids

Last updated: June 7, 2026

ATC S01B Anti-Inflammatory Agents patent landscape: market dynamics, exclusivity timelines, and generic entry risks

ATC S01B covers ophthalmic anti-inflammatory drugs across corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), and related anti-inflammatory combinations. Commercial dynamics are driven by (1) post-surgical demand (cataract, corneal procedures), (2) chronic ocular inflammation indications (uveitis variants, blepharitis-adjacent inflammatory syndromes), and (3) fixed-dose combinations that reduce dosing burden. Patent protection is fragmented by active ingredient, dosage form (solution, suspension, emulsion), and formulation attributes (particle size, surfactant system, preservative package, pH/viscosity profile), with the most durable exclusivity typically coming from secondary formulation or method-of-use patents rather than the original composition alone.

What drugs fall under ATC S01B anti-inflammatory agents, and which are the biggest revenue drivers?

ATC S01B is a therapeutic bucket used for high-level classification, not a legal IP grouping. The patent landscape and expiry calendars therefore need to be mapped drug-by-drug and formulation-by-formulation.

High-level categories within S01B

Corticosteroid anti-inflammatory eye drops (frequent in post-op care)

Key commercial themes:

• Prednisolone derivatives and related corticosteroids in multiple formulations (solution vs suspension)
• Steroid plus non-steroidal adjunct combinations in some post-op regimens
• Strategies to improve penetration, retention, and tolerability (particle engineering, suspending agents, preservative selection)

Ophthalmic NSAIDs (pain and inflammation, often adjacent to surgery)

Key commercial themes:

• NSAID monotherapy and post-procedure dosing schedules
• Formulation differentiation via viscosity modifiers, salt forms, and reduced irritation profiles

Combination anti-inflammatory products

Key commercial themes:

• Fixed-dose combinations can support differentiation even after active ingredient patents expire
• Formulation patents often cover preservative systems and release behavior

How strong is the patent estate for ophthalmic anti-inflammatory drops versus generics?

In practice, S01B patent estates vary materially by entry class:

Where estates are strongest

• Proprietary suspension technologies for corticosteroids (particle size distributions, crystallinity control, rheology)
• Fixed-dose combinations where at least one component has a later-expiring formulation or method-of-use patent
• Method-of-use patents tied to specific post-op surgical timing, dosing cadence, or patient sub-populations

Where estates are weakest

• Older actives with clear composition-of-matter coverage already expired
• Single-molecule solutions where differentiation is limited and generic bioequivalence is easier

Common litigation patterns that affect risk

• Paragraph IV challenges centered on formulation equivalence (same active, different excipient or particle engineering) and Orange Book listing coverage
• Settlement agreements that delay launch by creating “carve-outs” around later-listed patents while allowing early entry on non-covered strengths or regimens

When does exclusivity end for major S01B products, and what drives the end-date?

Exclusivity is typically a stack:

• Patent term (with potential patent term adjustment for some products)
• FDA marketing exclusivity (new chemical entity, new clinical investigation, orphan if applicable; ophthalmic products often hinge on patent term more than exclusivity)
• Device-delivery or regimen-specific exclusivity when method-of-use patents block generic launch

Practical timing rule for S01B: Generic risk starts when the last listed Orange Book patent is close to expiration or when a Paragraph IV settlement allows earlier entry. For ophthalmic drops, formulary changes and strength-specific labels frequently matter more than broad class-level timelines.

What patents protect ophthalmic anti-inflammatory agents (composition, formulations, and methods)?

For S01B, the patent estate is usually layered into three buckets:

1) Composition-of-matter (MoC)

• Coverage of the active ingredient itself or specific salts/derivatives
• Older MoC dominates the earlier expiry curve

2) Formulation and manufacturing patents

Common claim themes:

• Particle size and distribution for suspensions
• Surface treatment or milling conditions that change settling behavior
• Preservative systems that reduce corneal toxicity while maintaining antimicrobial efficacy
• Viscosity modifiers and surfactant packages improving wetting and retention

3) Method-of-use and treatment regimen patents

Common claim themes:

• Post-operative dosing schedule windows (for cataract and other ocular surgeries)
• Specific inflammatory disease subtypes, including dosing cadence and duration
• Combination method-of-use (steroid plus NSAID) for defined endpoints

What is the Orange Book status of ATC S01B anti-inflammatory agents?

Orange Book coverage is the gating mechanism for generic timelines. For ophthalmic anti-inflammatory drops, the “status” relevant to entry risk is not just whether there are listed patents, but:

• How many patents are listed per NDA
• Which patents are “new” (recent listings can extend practical launch timing)
• Whether listed patents cover the exact strength, dosage form, and labeling that the generic seeks

Because S01B spans multiple NDAs and dosage forms, Orange Book status must be assessed at the NDA/NDC level for each product.

How many patents cover major S01B products and what types dominate?

Within ophthalmic anti-inflammatory franchises, the typical pattern is:

• A small number of core MoC patents
• A larger set of secondary formulation and method-of-use patents
• Additional manufacturing patents that can become relevant if a generic’s process differs

The highest entry friction usually comes from:

• Later-listed patents (often formulation or method-of-use) that remain unexpired even after the active ingredient MoC expires
• Patent clusters that share priority dates but cover different claim scopes (same product, different formulation aspects)

Which companies control the ophthalmic anti-inflammatory market under S01B?

Market control is frequently held by branded originators and their line-extension strategies, with generics and challengers focusing on:

• Strength and dosing schedules aligned with label
• Preservation of bioavailability and tolerability
• Waivers and carve-outs negotiated through settlements

The competitive landscape typically includes:

• Originator ophthalmic franchises (multi-product portfolios in inflammation and post-op pain)
• Generic ophthalmic players active in Paragraph IV filing behavior
• Specialty ophthalmic companies that reposition formulation tech into follow-on NDAs

What Paragraph IV challenges are most common for S01B, and how do they change launch dates?

Paragraph IV filings for S01B typically fall into two buckets:

Filing type A: Active-ingredient entry against composition patents

• Works when composition and key formulation coverage expires early
• Risk is lower when only MoC is listed

Filing type B: Formulation and method-of-use entry against Orange Book-listed secondary patents

• Common when the originator has built a dense patent lattice around formulation attributes or regimen
• Launch timing depends on whether the generic “carves out” by not seeking a label that infringes method-of-use patents

Settlement dynamics most seen in S01B:

• Generic agrees to delay entry until a later-formulated or later-listed patent expires
• Parties split on which strengths or labeling regimens are launched at first entry
• Litigation can continue while regulatory approval (or readiness) proceeds under a delayed launch trigger

What patent litigation affects generic entry of ophthalmic anti-inflammatory drops?

Key litigation levers in S01B:

• Claim construction disputes around formulation equivalence
• Infringement arguments tied to specific formulation components (excipient package, particle behavior, preservative system)
• Procedural timing: preliminary injunction motions are less predictable than in systemic products, but settlements are common

Market impact:

• Even when a generic wins early, brand holders can maintain market share by shifting to later formulations or alternative strengths

How does ATC S01B anti-inflammatory patent coverage affect biosimilar or biologic competition?

S01B is overwhelmingly small-molecule ophthalmics rather than biologics. Biosimilar pathways are not the relevant competitive driver for most of the S01B segment. The dominant generic risk is conventional ANDA-driven entry against Orange Book patents for drops and suspensions.

What formulations are protected by patents in S01B, and where do generics hit barriers?

Corticosteroid suspensions

Barriers:

• Particle size distribution and suspension stability requirements
• Settling rate control and re-suspendability
• Rheology targets that mimic the branded dosing experience

NSAID solutions and suspensions

Barriers:

• Salt form and solubility control
• Viscosity and surface-active systems affecting ocular penetration
• Preservative tolerance profiles for chronic dosing labels

Fixed-dose combinations

Barriers:

• Combination method-of-use patents
• Formulation claim coverage on two-actives together, including ratio constraints and release characteristics

How does one S01B product compare with another in patent durability and generic readiness?

Durability drivers for comparison:

• Density of Orange Book listings (count and recency)
• Whether the “last expiring” patent is MoC vs formulation vs method-of-use
• Whether the generic must match label-specific regimen (post-op schedule, duration) to gain market access

Readiness drivers for comparison:

• Ease of manufacturing equivalent suspensions
• Preservation of stability during distribution
• Formulation feasibility for “label-matched” bioequivalence

Commercial dynamics: how do dosing patterns and delivery systems shape demand and IP strategy?

S01B commercial demand is shaped by:

• Surgical volumes and post-operative prescribing behavior
• Switching dynamics after safety or tolerability signals
• Preference for dosing convenience in post-op care (timing adherence)
• Cost pressures that accelerate generic substitution once patent and regulatory barriers fall

Originators respond with:

• Line extensions via new NDA(s) that change formulation characteristics
• Label updates tied to method-of-use patent claims
• Portfolio bundling and channel strategy for wholesalers and IDNs

What generic entry risks exist for ATC S01B ophthalmic anti-inflammatory agents?

Primary risks:

• “Patent cliffs” when the last listed Orange Book patent expires and no later secondary patents remain
• Litigation-driven launch delays that can reverse if settlements lock in later entry dates
• Label carve-outs that let generics enter while leaving subsets of claims unchallenged

Secondary risks:

• Revisions to preservative system or particle engineering that can trigger separate patent coverage
• Difficulty in achieving suspension stability without infringing formulation claims

Key takeaways

• ATC S01B market dynamics are dominated by post-operative inflammation demand and formulation differentiation that extends practical exclusivity.
• The strongest IP barriers typically come from formulation and method-of-use patents listed in the Orange Book close to the end of the patent term.
• Paragraph IV challenges for ophthalmic anti-inflammatories often target secondary patents, not just composition-of-matter.
• Generic entry risk is product-specific and strength/label-specific due to method-of-use and formulation claim scopes.

FAQs

Which active ingredients in S01B face the highest generic substitution risk?

Substitution risk is highest for older actives with sparse secondary formulation and method-of-use Orange Book listings.

Do S01B settlements usually delay entry, or can they enable earlier carve-out launches?

Both occur; the dominant pattern is delayed entry for covered patents while enabling carve-out launches on non-covered strengths or regimens.

What patent types most often survive after the composition-of-matter expires in S01B?

Formulation stability, particle characteristics, preservative systems, and method-of-use regimen patents.

How does changing excipients affect infringement risk in ophthalmic anti-inflammatory ANDAs?

Even if the active ingredient is the same, excipient and particle engineering differences can still fall within formulation claim scope or be treated as design-around failures depending on claim language.

Is biosimilar competition relevant to ATC S01B?

For most S01B products, no. Competition is primarily ANDA-based for small-molecule ophthalmics.

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
2. World Health Organization Collaborating Centre for Drug Statistics Methodology. ATC classification: S01B Anti-inflammatory agents. https://www.whocc.no/atc_ddd_index/